Ngā hua rapu - Jason Gotlib

Whakamahine hua
  1. 1
    Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation

    Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation mā Jason Gotlib

    I whakaputaina 2005
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    How I treat atypical chronic myeloid leukemia

    How I treat atypical chronic myeloid leukemia mā Jason Gotlib

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    World Health Organization‐defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management

    World Health Organization‐defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management mā Jason Gotlib

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    World Health Organization‐defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management

    World Health Organization‐defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management mā Jason Gotlib

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    World Health Organization‐defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management

    World Health Organization‐defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management mā Jason Gotlib

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    World Health Organization‐defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management

    World Health Organization‐defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management mā Jason Gotlib

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Myeloid neoplasms with eosinophilia

    Myeloid neoplasms with eosinophilia mā Andreas Reiter, Jason Gotlib

    I whakaputaina 2016
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    World Health Organization‐defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management

    World Health Organization‐defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management mā William Shomali, Jason Gotlib

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management

    World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management mā William Shomali, Jason Gotlib

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management

    World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management mā William Shomali, Jason Gotlib

    I whakaputaina 2024
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Hypereosinophilic Syndrome and Clonal Eosinophilia: Point-of-Care Diagnostic Algorithm and Treatment Update

    Hypereosinophilic Syndrome and Clonal Eosinophilia: Point-of-Care Diagnostic Algorithm and Treatment Update mā Ayalew Tefferi, Jason Gotlib, Animesh Pardanani

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis

    New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis mā Andreas Reiter, Tracy I. George, Jason Gotlib

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment

    The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment mā Jason Gotlib, Julia E. Maxson, Tracy I. George, Jeffrey W. Tyner

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management

    The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management mā Jason Gotlib, Jan Cools, James Malone, Stanley L. Schrier, D. Gary Gilliland, Steven Coutré

    I whakaputaina 2003
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations

    Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations mā Robert S. Ohgami, Lisa Ma, Jason D. Merker, Jason Gotlib, Iris Schrijver, James L. Zehnder, Daniel A. Arber

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in <i>Caenorhabditis elegans</i> and <i>Homo sapiens</i>

    Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in <i>Caenorhabditis elegans</i> and <i>Homo sapiens</i> mā Massa J. Shoura, Idan Gabdank, Loren Hansen, Jason D. Merker, Jason Gotlib, Stephen D. Levene, Andrew Fire

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    The serum tryptase test: an emerging robust biomarker in clinical hematology

    The serum tryptase test: an emerging robust biomarker in clinical hematology mā Peter Valent, Wolfgang R. Sperr, Karl Sotlar, Andreas Reiter, Cem Akin, Jason Gotlib, Hans-Peter Horny, Michel Arock

    I whakaputaina 2014
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Treatment advances have not improved the early death rate in acute promyelocytic leukemia

    Treatment advances have not improved the early death rate in acute promyelocytic leukemia mā James Scott McClellan, Holbrook E. Kohrt, Steven Coutré, Jason Gotlib, Ravindra Majeti, Ash A. Alizadeh, Bruno C. Medeiros

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation.

    Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation. mā William Wallace, Stephen T. Ahlers, Jason Gotlib, Valentin Bragin, J. Sugár, R Gluck, Paul Shea, Keith L. Davis, Vahram Haroutunian

    I whakaputaina 1993
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I

    Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I mā Ruben A. Mesa, Srđan Verstovšek, Vikas Gupta, John Mascarenhas, Ehab Atallah, Timothy C. Burn, William Sun, Victor Sandor, Jason Gotlib

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: